loading page

Radiologic Response to MEK Inhibition in a Patient with a WNT-activated Craniopharyngioma
  • +4
  • Krupesh Patel,
  • Jeffrey Allen,
  • David Zagzag,
  • Jeffrey Wisoff,
  • Alireza Radmanesh,
  • Tatyana Gindin,
  • Theodore Nicolaides
Krupesh Patel
NYU
Author Profile
Jeffrey Allen
NYU Langone Health
Author Profile
David Zagzag
NYU Langone Health
Author Profile
Jeffrey Wisoff
NYU Langone Health
Author Profile
Alireza Radmanesh
NYU Langone Health
Author Profile
Tatyana Gindin
NYU Langone Health
Author Profile
Theodore Nicolaides
NYU Langone Health
Author Profile

Abstract

Craniopharyngiomas are benign brain tumors that can often be cured surgically. A small fraction of unresectable tumors can progress and cause significant morbidity and even death. Unfortunately, WNT activated tumors lack clinically-validated targeted therapies in the pediatric population. Herein, we describe a patient with a multiply recurrent adamantinomatous craniopharyngioma with WNT activation. We utilized the MEK inhibitor binimetinib with noted interval decrease in tumor size. This demonstrates the possible utility of MEK inhibitors in WNT activated craniopharyngiomas.